Good MorningEquity markets slowed their declines, but new lows were set on Thursday. The move lower may have ended, but there is a risk that it will deepen before the bottom is hit. The market is repricing the odds of FOMC rate cuts, which will have far-reaching ramifications for stocks. The takeaway is that the outlook for earnings growth in the 2nd half is flawed.
The best target for solid support for the S&P 500 is near 4,800 and the prior all-time highs. That level is a significant pivot crossed earlier this year that has yet to be confirmed as support. If support is confirmed, new all-time highs are likely by the end of the year. If not, this market could sell off for several months and be down 20% to 30% from its highs.
Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Consumer Staples | |
Thinking about investing in PepsiCo? PepsiCo (NASDAQ: PEP) is the world’s 2nd largest consumer food company behind Nestle. It is the US's largest consumer food company, growing domestically and internationally. It is an attractive stock for many reasons.
The company's deeply rooted history... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Transportation | |
CSX Corporation (NASDAQ: CSX) is a leading North American freight railroad operator. The railroad and railway sub-sector operates within the broader transportation sector. CSX’s earnings report was recently released and exceeded market expectations in its first quarter of 2024. The company's... Read the Full Story |
|
Markets | |
A new business cycle is underway for the United States economy, and the manufacturing sector could be in play. This time, it isn't only Wall Street pushing the bets forward but also the current administration's attempt to onshore some global steel and aluminum manufacturing jobs.
So far, markets ... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Markets | |
As investors search for safe havens in volatile markets, bear market funds are gaining popularity as a diversified asset class designed to withstand exceptionally volatile markets. While bear market funds can be appealing during periods of economic downturn due to their potential to produce return... Read the Full Story |
|
Auto/Tires/Trucks | |
In 2024, Tesla (NASDAQ: TSLA) finds itself navigating through a year filled with turbulence, starkly contrasting its historical performance as a leader in the electric vehicle and technology sectors. With shares plummeting, Tesla now holds the unfortunate title of being the worst-performing S&... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Construction | |
As many reasons as there are to be skeptical of the rally in homebuilder stocks, names like D.R. Horton (NYSE: DHI) are trending higher and will continue to rise. They rise because the industry normalized and the business provides value for shareholders. That’s a blunt way of putting it, but... Read the Full Story |
|
Technology | |
In last week’s stock options article, we reviewed the pros and cons of debit spreads. When you believe a stock is going higher but want to limit your downside risk and are willing to cap upside gains to spend less on the trade, then a call debit spread can be a viable choice. In the same vei... Read the Full Story |
|
Consumer Discretionary | |
After having one of the best two-year performances in the technology sector, shares of Netflix Inc. (NASDAQ: NFLX) are at an inflection point. Markets may wonder whether the stock will make a new all-time high or give up some of the stellar gains it gave investors after the COVID-19 pandemic.
Wit... Read the Full Story |
|
Technology | | Stock buybacks, also called stock repurchases, are important drivers of shareholder value, which is one of the reasons why Marketbeat tracks the data. As the name suggests, a buyback is when a company buys back its own shares from the market.
Buybacks are a form of capital return that can offset t... Read the Full Story |
|
Technology | |
Artificial intelligence (AI) is propping up the computer and technology sector, but it's also helping many other industries involved in collecting, procuring and providing real-time data. Planet Labs PBC (NYSE: PL), which was started by NASA scientists in 2010, operates a network of over 200 sate... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. | | View Today's Stock Pick |
|
